To the Editor:

Hodgkin lymphoma (HL), accounting for \~10% of lymphomas diagnosed in the United States ([@R1]), have a largely favorable outcome (5-year survival 85%) that may be improved with anti-CD30-drug conjugates or checkpoint inhibitors ([@R2], [@R3]). However, relapsed/refractory HL has poor outcomes and necessitates intensive salvage chemotherapy and/or autologous hematopoietic cell transplantation ([@R4]). Factors classifying HL relapse/refractory risk are needed for determining optimal treatment strategies ([@R5]). Therefore, identifying key factors underlying the mechanisms of HL cell survival and maintenance are necessary to uncover new therapeutic targets and/or develop innovative strategies to increase cure rates and long-term disease control while limiting toxicities in HL patients.

Apoptotic signals triggered by oncogenic stress or chemotherapies are countered by increased expression of anti-apoptotic BCL-2 family members ([@R6]). Consequently, specific inhibitors to anti-apoptotic family members (BCL-2, BCL-XL, MCL-1) have been developed, such as venetoclax that inhibits BCL-2 ([@R7]). Unfortunately, most B-cell lymphomas have proven resistant to venetoclax, likely due to their dependency on other anti-apoptotic BCL-2 family proteins ([@R8]). Our analysis of ∼2300 B-cell lymphoma samples revealed the understudied anti-apoptotic BCL-2 family member *BCL-W* was elevated in six different types of B-cell lymphoma, including HL ([@R9]). We report here a comprehensive investigation into the contribution of BCL-W in HL cell survival, a mechanism of its overexpression, and its potential as a diagnostic and prognostic biomarker for HL.

To gain insight into the contribution of BCL-W to HL, we first performed a bioinformatic analysis of ∼250 patient samples ([Supplementary Tables S1](#SD1){ref-type="supplementary-material"}--[2](#SD1){ref-type="supplementary-material"}), which showed *BCL-W* mRNA, but not *BCL-2* (negative control), was significantly overexpressed in HL compared to normal B-cells ([Fig. 1A](#F1){ref-type="fig"}). *BCL-XL* mRNA was also significantly increased in HL ([Fig. 1A](#F1){ref-type="fig"}), consistent with published BCL-XL immunohistochemistry data ([@R10], [@R11]). Analogous results were obtained from data of laser-microdissected HL cells compared to purified normal germinal center centrocytes and centroblasts ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Further evaluation showed a significant inverse association of *BCL-W* and *BCL-2* expression, whereas *BCL-W* and *BCL-XL* expression had a significant positive association ([Supplementary Fig. S2A](#SD1){ref-type="supplementary-material"}). *BCL-2* and *BCL-XL* expression had no significant associations. Additionally, the majority (67.3%) of cases had increased *BCL-W* expression above the mean of the normal control samples, and increased *BCL-XL* expression, but not *BCL-2*, was also a frequent event ([Fig. 1B](#F1){ref-type="fig"}). Notably, 94.9% of the samples had elevated levels of *BCL-W*, *BCL-XL*, or both above the mean of the normal B-cells ([Supplementary Fig. S2B](#SD1){ref-type="supplementary-material"}) with the majority overexpressing both *BCL-W* and *BCL-XL* (Spearman's correlation coefficient *ρ*=0.18, *P*=5.45×10^−3^; [Fig. 1C](#F1){ref-type="fig"}), suggesting co-overexpression of *BCL-W* and *BCL-XL* may be important in HL pathogenesis.

Next, we investigated whether *BCL-W* levels would be differentially expressed depending on the clinical features of HL patients. *BCL-W* was significantly elevated in the common nodular sclerosis subtype ([Supplementary Fig. S3A](#SD1){ref-type="supplementary-material"}), whereas due to sample size there was only a trend toward elevated *BCL-W* expression in the mixed cellularity subtype ([Supplementary Fig. S3A](#SD1){ref-type="supplementary-material"}). Significantly increased *BCL-W* levels were detected in early- and late-stage HL ([Supplementary Fig. S3B](#SD1){ref-type="supplementary-material"}). However, when divided into individual stages, *BCL-W* expression increased as stage increased ([Fig. 1D](#F1){ref-type="fig"}), suggesting *BCL-W* expression may correlate with disease severity. In support of this, *BCL-W* levels were significantly elevated in relapsed/refractory samples, and were significantly higher in those that relapsed early (≤5 years) versus those that relapsed later (\>5 years) ([Fig. 1E](#F1){ref-type="fig"}, [Supplementary Fig. S3C](#SD1){ref-type="supplementary-material"}). *BCL-W* levels were also significantly higher in patients with a high international prognostic score (IPS) (\>3--7) versus those with lower IPS (0--3) ([Fig. 1F](#F1){ref-type="fig"}). Therefore, increased *BCL-W* expression correlates with aggressive, relapsed/refractory HL.

Although Epstein-Barr virus (EBV) contributes to HL pathogenesis ([@R12]), EBV status did not alter the increased *BCL-W* levels in HL samples above the normal control B-cells ([Supplementary Fig. S3D](#SD1){ref-type="supplementary-material"}). Also, there was no significant difference in *BCL-W* expression between younger (\<50 years-old) and older (≥50 years-old) patients or between genders ([Supplementary Fig. S3E](#SD1){ref-type="supplementary-material"}--[F](#SD1){ref-type="supplementary-material"}). *BCL-2* expression (negative control) was not significantly different from that in normal B-cells for any characteristics ([Fig. 1D](#F1){ref-type="fig"}--[F](#F1){ref-type="fig"}, [Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}), whereas *BCL-XL* expression was similar to the results obtained for *BCL-W* for each of the characteristics ([Supplementary Fig. S4](#SD1){ref-type="supplementary-material"}). Collectively, our data demonstrate that *BCL-W* and *BCL-XL* expression correlate with HL severity and treatment response, which could serve as novel, much-needed biomarkers of risk for early relapse, treatment-resistant HL.

Subsequently, we performed IHC on 48 HL patient samples ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}; 15 previously evaluated ([@R9])), which showed increased BCL-W protein is a very frequent event in HL. All but one of the 48 patient samples had positive staining (≥1 pathologist score) for BCL-W ([Fig. 1G](#F1){ref-type="fig"}) with 94% (45 of 48) having high BCL-W levels (scoring 2+ or 3+). Only 14 cases, with the majority being scored 1+, showed any BCL-2 staining ([Fig. 1G](#F1){ref-type="fig"}, [Supplementary Fig. S5A](#SD1){ref-type="supplementary-material"}). To investigate whether copy number gains in chromosome 14 or *BCL-W*'s genetic locus could explain how BCL-W is overexpressed in HL, we performed dual-colored fluorescence *in situ* hybridization (FISH) on touch-preparation HL samples using two probes: one *BCL-W*-specific (red) and one chromosome 14 centromere-specific (green) as a control. Eight of 14 samples had significantly more *BCL-W* signals than centromeric signals in the Hodgkin Reed-Sternberg (HRS) cells ([Fig. 1H](#F1){ref-type="fig"}, [Supplementary Table S4](#SD1){ref-type="supplementary-material"}). Twelve of 14 had more *BCL-W* signals compared to background lymphocytes ([Fig. 1H](#F1){ref-type="fig"}). To assess the relationship between *BCL-W* copy number and RNA expression, *BCL-W* FISH, using a second independent probe ([@R13]) binding next to *BCL-W*, and qRT-PCR were performed on 10 HRS cell-rich FFPE HL samples. All samples had elevated *BCL-W* mRNA levels ([Supplementary Fig. S5B](#SD1){ref-type="supplementary-material"}) and all had increased *BCL-W* FISH signals in lymphoma cells compared to background lymphocytes ([Supplementary Fig. S5C](#SD1){ref-type="supplementary-material"}, [Supplementary Table S5](#SD1){ref-type="supplementary-material"}). There was a significant positive correlation between the number of *BCL-W* FISH signals and *BCL-W* mRNA levels (Spearman's correlation coefficient *ρ*=0.97, *P*=5.44×10^−6^; [Fig. 1I](#F1){ref-type="fig"}). Thus, amplification of the region containing *BCL-W* and/or copy number gains of chromosome 14 is one mechanism of BCL-W overexpression in HL.

Next, we investigated whether *BCL-W* and/or *BCL-XL* contributed to HL cell survival. mRNA ([Fig. 2A](#F2){ref-type="fig"}) and protein ([Fig. 2B](#F2){ref-type="fig"}) levels of all five anti-apoptotic BCL-2 family members in three HL cell lines compared to normal controls (B-cells, lymph node, spleen) showed only BCL-W and BCL-XL were elevated. To pharmacologically inhibit BCL-W and BCL-XL, we used navitoclax (ABT-263), which inhibits BCL-W, BCL-XL, and BCL-2. All HL cell lines were sensitive to navitoclax, even at low concentrations ([Fig. 2C](#F2){ref-type="fig"}). Decreased cell growth following navitoclax was due to loss of viability ([Supplementary Fig. S6](#SD1){ref-type="supplementary-material"}) from apoptosis (Annexin-V-positive cells; [Fig. 2D](#F2){ref-type="fig"}).

To differentiate the effects of navitoclax inhibiting BCL-W from that of inhibiting BCL-XL and/or BCL-2, we targeted only BCL-XL (A-1155463), only BCL-2 (venetoclax, ABT-199), or both. Currently, no BCL-W-specific inhibitors exist. Two HL lines (U-HO1, L-428) with the highest levels of BCL-XL protein showed sensitivity to BCL-XL inhibition, whereas KM-H2 with lower BCL-XL levels had little response ([Fig. 2C](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}, [Supplementary Fig. S6](#SD1){ref-type="supplementary-material"}). Only L-428 responded to BCL-2 inhibition at high concentrations ([Fig. 2C](#F2){ref-type="fig"}). Combination treatment with both BCL-XL- and BCL-2-specific inhibitors yielded no effects beyond that with BCL-XL inhibition alone ([Fig. 2C](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}, [Supplementary Fig. S6](#SD1){ref-type="supplementary-material"}). Likely due to a lack of MCL-1 detected in HL ([Fig. 2A](#F2){ref-type="fig"}--[B](#F2){ref-type="fig"}), there was no change in cell growth, viability, or apoptosis following MCL-1 inhibition (A-1210477; [Supplementary Fig. S7](#SD1){ref-type="supplementary-material"}). Although no BCL2-A1/BFL-1-specfic inhibitor exists, we predict little effect from its inhibition since HL cells have low BCL2-A1/BFL-1 levels ([Fig. 2A](#F2){ref-type="fig"}--[B](#F2){ref-type="fig"}). BCL-XL inhibition accounted for only a portion of the apoptosis from navitoclax treatment; therefore, BCL-XL contributes to HL cell survival, but BCL-W must have a significant role.

To determine the dependence of HL on BCL-W specifically, we utilized doxycycline-inducible *BCL-W* shRNA in U-HO1 and KM-H2 HL lines, representing the most common HL subtypes, nodular sclerosing and mixed cellularity, respectively. Following induction of *BCL-W* shRNA, BCL-W protein levels decreased ([Fig. 2E](#F2){ref-type="fig"}). BCL-XL levels remained unchanged. *BCL-W* knockdown significantly reduced cell growth ([Fig. 2F](#F2){ref-type="fig"}), live cell numbers ([Supplementary Fig. S8](#SD1){ref-type="supplementary-material"}), and viability ([Fig. 2G](#F2){ref-type="fig"}) due to increased apoptosis (Annexin-V positivity, [Fig. 2H](#F2){ref-type="fig"}; cleaved Caspase 3, [Fig. 2E](#F2){ref-type="fig"}). Therefore, BCL-W is essential for HL cell survival.

In conclusion, although advances in treatments have substantially increased the possibility of a cure for HL patients, those with refractory HL or who relapse still have a poor prognosis ([@R4]). Our results identify novel therapeutic targets and predictive biomarkers for patients with HL, an unmet need. Here, we revealed an essential survival role of BCL-W in HL and that its overexpression was frequently due to *BCL-W* copy number gains from regional amplification of *BCL-W* or polyploidy, suggesting additional copies of *BCL-W* contribute to HL pathogenesis. Moreover, since HL samples frequently co-overexpressed *BCL-W* and *BCL-XL* and HL cells relied on them both and not on MCL-1 or BCL-2 for survival, there is un-tapped potential of targeting BCL-W and BCL-XL, possibly with navitoclax, in combination with other anti-cancer therapies in HL. In support of this idea, navitoclax increased sensitivity of HL lines to conventional chemotherapy, brentuximab-vedotin, and ruxolitinib ([@R14], [@R15]). Combination treatment strategies targeting BCL-W and BCL-XL may be especially beneficial for relapse/refractory HL, as levels of both increased with increasing disease severity and risk of poor outcome.
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![BCL-W overexpression in HL is a frequent event, associates with increased severity of disease, and occurs, in part, to increased copy number.\
**A,** Gene expression data (log~2~) for *BCL-W*, *BCL-2*, and *BCL-XL* mRNA in HL (*n*=254) compared with normal human B-cells (*n*=111); \**P*=1.76×10^−6^ and \*\**P*=2.14×10^−20^, two-tailed *t*-tests. **B,** Heatmap illustrating the fold-change differences in gene expression above (red) or below (blue) the mean of the normal B-cell controls (white) for the three genes. The *BCL-W* fold-change was ranked highest to lowest for all 254 HL samples with the fold-changes for *BCL-XL* and *BCL-2* for each patient sample aligned under *BCL-W*. Each vertical line represents one patient. **C,** Scatter plot of HL patients with fold-change (log~2~) mRNA expression of *BCL-W*, *BCL-XL*, or both above the mean of normal B-cells. Each dot represents one sample (*BCL-W* + *BCL-XL*, *n*=159; *BCL-W*, *n*=12; *BCL-XL*, *n*=70); Spearman's correlation coefficient *ρ*=0.18, *P*=5.45×10^-3^. **D-F**, Gene expression data (log~2~) for *BCL-W* and *BCL-2* based on stratification into individual stages (**D**); non-relapse/refractory (Non-R/R), early relapse, late relapse, and refractory (**E**); and low (0--3) and high (\>3--7) international prognostic score (**F**). HL samples were compared with normal B-cell controls (**D-F**) and between HL sample groups (**F)**. For **D,** \**P*\<0.012 and \*\**P*=2.73×10^−4^; for **E,** \**P*=0.049, \*\**P*=4.61×10^−3^, and \*\*\**P*=1.80×10^−3^; for **F,** \**P*=0.034, \*\**P*=2.74×10^−4^, and \*\*\**P*=2.13×10^−6^; two-tailed *t*-tests; ns, no statistical significance. Number of samples (*n*) is indicated. **G,** Immunohistochemistry (IHC) of BCL-W and BCL-2 protein in HL patient samples (*n*=48). Box and whisker plot of pathologist scores (left) and representative images (middle, 40X objective, 3+) of BCL-W staining are shown (\**P*\<0.0001, two-tailed *t*-test). Heatmap (right) showing the IHC pathologist score for BCL-W and BCL-2 within the same individual patient sample. **H,** Representative images (left, 100X objective) of FISH analysis for the genomic locus that includes *BCL-W* (red) and chromosome 14 centromere (green) as a control in HL patient samples. Normal lymphocytes (control) and two representative images of Hodgkin Reed-Sternberg (HRS) cells are shown. FISH signals were quantified in 25 HRS cells in 14 patient samples and the number of *BCL-W* signals above the number of centromere signals were graphed for each patient (right). **I,** Spearman's correlation comparing the number of *BCL-W* FISH signals to the fold-change in *BCL-W* mRNA (determined by comparing each HL sample to the mean of the normal samples) for the 10 HL patient samples evaluated (see [Supplementary Fig. S5B](#SD1){ref-type="supplementary-material"}--[C](#SD1){ref-type="supplementary-material"}). Spearman's correlation coefficient and *P*-value are indicated.](nihms-1538535-f0001){#F1}

![Hodgkin lymphoma cells undergo apoptosis following pharmacological inhibition of BCL-W and BCL-XL and after knockdown of *BCL-W*.\
**A** and **B,** qRT-PCR analysis (**A,** in triplicate, \**P*\<0.0001; one-way ANOVA) and Western blotting (**B**) for the anti-apoptotic BCL-2 family members in HL cell lines (U-HO1, KM-H2, and L-428) and normal human controls (purified B-cells, lymph node (LN), and spleen). **C-D,** HL cell lines were either administered ABT-263/navitoclax (BCL-W, BCL-2, BCL-XL inhibitor; BCL-W/2/Xi); ABT-199/venetoclax (BCL-2 inhibitor; BCL-2i); A-1155463 (BCL-XL inhibitor; BCL-Xi); or a combination of ABT-199 and A-1155463 at the indicated concentrations in C or at 10μM in D. DMSO served as vehicle control. Forty-eight hours following treatment, cell growth was measured by MTS assays (**C,** in quadruplicate) and apoptosis by Annexin-V staining (**D,** in triplicate). For C-D, \**P*\<2.9×10^−5^, two-tailed *t*-tests. **E-H,** HL cell lines (U-HO1, KM-H2) were infected with lentivirus encoding two different doxycycline (Dox)-inducible shRNA against *BCL-W* (BCLW-1 or BCLW-2) or a non-targeting shRNA control (NT). Following addition of Dox to induce shRNA expression or PBS (vehicle control, Veh), Western blotting (**E**; CC3, cleaved Caspase 3) and MTS assays to measure cell growth (**F,** in quadruplicate) were performed. Viability (**G**, in triplicate) was determined by Trypan Blue Dye exclusion, and Annexin-V staining (**H,** in triplicate) was performed at the indicated intervals. For F-H, \**P*\<2.5×10^−2^, two-tailed *t*-tests. A representative experiment of 2--4 independent experiments performed for each assay for each cell line is shown.](nihms-1538535-f0002){#F2}
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